UNSPSC 51401602: Brotizolam

This classification denotes a benzodiazepine with the molecular formula C15H10BrClN4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5XZM1R3DKF, chemically known as 8-bromo-6-(o-chlorophenyl)-1-methyl-4h-s-triazolo(3,4c)thieno(2,3e)-1,4-diazepine but generally known as brotizolam, which bears US NIH Compound Identifier 2451. European Medicines Agency schedules Brotizolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05933MIG.

UNSPSC 51401602 Brotizolam, a Commodity code, shows limited recent state and local procurement activity directly aligned with the pharmaceutical substance named. The recent opportunities tagged to this code predominantly involve procurement of broader pharmaceutical products and services—naloxone, over-the-counter medications, generic pharmaceuticals, and direct-to-manufacturer prescription programs—rather than brotizolam specifically. State and local buyers soliciting under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. Work being solicited includes the purchase and distribution of pharmaceutical products through authorized wholesalers, naloxone acquisition for community health initiatives, and exploration of direct-to-manufacturer pharmacy benefit arrangements.

Activity is geographically dispersed across Florida, Texas, and Minnesota, with the cooperative purchasing vehicle (MMCAP) serving multistate participation including Oregon. Representative recent opportunities include Seminole County, Florida's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries, the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products with awards effective July 1, 2026. The code appears underutilized for brotizolam specifically; procurement activity tagged to it reflects general pharmaceutical purchasing and supply chain initiatives rather than demand for this particular controlled substance.